ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Professor Desire Collen Will Remain as Chairman of the Board and
01-Sep-2008 -
ThromboGenics NV announced that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer onSeptember 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member ...
Belgium
biotechnology
clinical trials
+4